Aptargroup/$ATR
AptarGroup shares rise after Q3 adjusted earnings and revenue beat expectations, with the company also raising its quarterly dividend.
7 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Aptargroup
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
- Ticker
- $ATR
- Sector
- Materials
- Primary listing
- NYSE
- Employees
- 14,000
- Headquarters
- Crystal Lake, United States
- Website
- www.aptar.com
Aptargroup Metrics
BasicAdvanced
$8.3B
23.54
$5.55
0.34
$1.92
1.47%
Price and volume
Market cap
$8.3B
Beta
0.34
52-week high
$146.91
52-week low
$103.23
Average daily volume
477K
Dividend rate
$1.92
Financial strength
Current ratio
1.614
Quick ratio
0.963
Long term debt to equity
0.418
Total debt to equity
0.511
Dividend payout ratio (TTM)
33.84%
Interest coverage (TTM)
7.74%
Profitability
EBITDA (TTM)
798.404
Gross margin (TTM)
36.07%
Net profit margin (TTM)
9.22%
Operating margin (TTM)
12.50%
Effective tax rate (TTM)
20.15%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
6.14%
Return on equity (TTM)
13.46%
Valuation
Price to earnings (TTM)
23.541
Price to revenue (TTM)
2.145
Price to book
3.16
Price to tangible book (TTM)
5.33
Price to free cash flow (TTM)
27.355
Free cash flow yield (TTM)
3.66%
Free cash flow per share (TTM)
4.776
Dividend yield (TTM)
1.47%
Forward dividend yield
1.47%
Growth
Revenue change (TTM)
8.93%
Earnings per share change (TTM)
-4.15%
3-year revenue growth (CAGR)
5.09%
10-year revenue growth (CAGR)
5.35%
3-year earnings per share growth (CAGR)
13.65%
10-year earnings per share growth (CAGR)
6.06%
3-year dividend per share growth (CAGR)
7.53%
10-year dividend per share growth (CAGR)
4.82%
What the Analysts think about Aptargroup
Analyst ratings (Buy, Hold, Sell) for Aptargroup stock.
Analyst projections of the future price of Aptargroup stock.
Bulls say / Bears say
Core sales rose 5% in the third quarter, with Beauty up 8% and Closures up 11%, showing growth across Aptar’s businesses rather than reliance on one segment. (AptarGroup)
Pharma core sales grew 8% after excluding emergency-medicine destocking, supported by injectables and consumer healthcare demand. Aptar’s acquisition of PULMOTREE adds a non-propellant inhaler platform that could extend its respiratory drug-delivery opportunities. (AptarGroup, Aptar)
Management expects fourth-quarter adjusted EPS of $1.39–$1.47 and says the emergency-medicine destocking headwind should abate, creating scope for an earnings rebound after a weak year-to-date. (AptarGroup)
Profitability is under pressure: third-quarter adjusted EBITDA margin fell to 21.3% from 23.2%, while adjusted EPS declined to $1.52 from $1.62. All three segments reported lower margins. (AptarGroup)
Aptar lost control of its Russian subsidiary and recorded a $60.4 million after-tax charge, including about $30 million of cash it can no longer access. This creates a direct earnings hit and highlights exposure to government action in foreign markets. (AptarGroup)
Pharma, Aptar’s key profit engine, grew only 1% on a core basis in the quarter as emergency-medicine sales fell; management had expected a roughly $65 million full-year reduction from this destocking. That makes the near-term growth outlook sensitive to whether demand normalises as forecast. (AptarGroup)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
Aptargroup Financial Performance
Revenues and expenses
Aptargroup Earnings Performance
Company profitability
Upcoming events
Aptargroup News
AllArticlesVideos
Funds containing Aptargroup
AllUSDEURGBP
Fund name | Fund size | $ATR weighting |
|---|---|---|
SPDR S&P US Dividend Aristocrats€SPYD | $3.8B | 0.33% |
SPDR S&P US Dividend Aristocrats£USDV | $3.8B | 0.33% |
SPDR S&P 400 US Mid Cap£SPX4 | $6.4B | 0.24% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.4B | 0.24% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.19% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.